Lung Transplant Hazard May Rise with Obese Recipients, Smoking Donors
Study found more 'primary graft dysfunction,' which is tied to higher death risk Source: HealthDay Related MedlinePlus Pages: Lung Transplantation, Obesity
This study provides a possible reason why genes carrying health risks have persisted in human populations. The second found evidence for multiple variants in genes related to ageing that exhibited antagonistic pleiotropic effects. They found higher risk allele frequencies with large effect sizes for late-onset diseases (relative to early-onset diseases) and an excess of variants with antagonistic effects expressed through early and late life diseases. There also exists other recent tangible evidence of antagonistic pleiotropy in specific human genes. The SPATA31 gene has been found under strong positive genomic sele...
Laparoscopic sleeve gastrectomy (LSG) has been associated with efficient and durable weight loss in obese patients with advanced heart failure (AHF) who undergo LVAD support. However, the effects of this combinatory approach on myocardial recovery remain undefined. Thus, we sought to evaluate the potential association between the combination therapy (LVAD support and LSG) and myocardial recovery in this patient cohort.
A body mass index (BMI)> 35 kg/m2 is a contraindication to transplantation in patients with end-stage heart failure. In these patients, bariatric surgery can be considered either concomitantly with continuous-flow left ventricular assist device (CF-LVAD) placement, or staged after CF-LVAD has been placed. We sought to evaluate the outcomes for these approaches.
We describe our early outcomes using the complete sternal-sparing (CSS) approach for HeartMate 3 (HM3) implantation in obese patients.
Clinical outcomes in heart failure patients with BMI> 30 are better than their normal weight counterparts; however obese patients have worse outcomes after heart transplantation. The aim of the present study was to investigate the impact of obesity on post-transplant outcomes in patients bridged to transplantation with left ventricular assist devices
As the population becomes increasingly obese, so does the pool of potential organ donors. However, many centers are hesitant to accept hearts from morbidly obese donors, limiting the donor pool. We hypothesized that utilization of hearts from obese donors would not impact recipient outcomes. .
Obesity and overweight have become a global epidemic and are associated with an increased risk for cardiovascular disease. Immunosuppressive medications carry the risk of weight gain and further challenge heart transplantation (HT) patients. Since both fat mass (FM) and fat-free mass (FFM), each with its discrete features, contribute to total body weight (TBW), we aimed to characterize the post-HT change in TBW and its implications for HT outcomes.
Overweight and obesity are not unexpected following heart transplantation (HTx). The variability in body mass index (BMI) of populations has been observed, yet no study has addressed BMI disparities after HTx in different countries. We thus examined the variability in BMI of HTx recipients among countries who participated in the multi-continental BRIGHT study.
Certain donor characteristics after heart transplantation (HTx) may have less optimal outcome post-HTx. One factors leading to worse outcome is female donors to male recipient possibly due to size (height and weight) mismatch relative to male donors. We try to compensate for this size mismatch by using obese female donors into male recipients. However, there have been recent concerns with obese donors, in the sense that there are commonly large fat deposits on the donor heart. It is not known whether short and obese female donors (weight oversizing) results in acceptable outcome after HTx.
Lung transplantation (Tx) is a life-saving treatment for terminal lung diseases but long-term outcomes are poor, beginning with possible development of primary graft disease (PGD) in the first few days post-Tx. PGD mainly involves hyperactivation of innate immunity, but as CD4+FOXP3+ T-regulatory (Treg) cells can curtail various types of inflammation, we wondered whether patients who develop PGD might have dysfunctional Treg cells.